Loading
The once-daily MET inhibitor tepotinib shrank tumours in about half of patients with MET exon 14-skipping lung cancer, detected either in tissue or in a blood test, supporting approval and the use of liquid biopsy to find the alteration.
Phase 2 study of 152 patients with advanced non-small-cell lung cancer with MET exon 14 skipping detected by liquid or tissue biopsy treated with tepotinib 500 mg daily.
Objective response by independent review was 46 percent overall (48 percent in liquid-biopsy and 50 percent in tissue-biopsy groups) with a median duration of response of 11.1 months; peripheral oedema was the main toxicity.
Tepotinib is an approved alternative to capmatinib for MET exon 14 lung cancer, and the trial validated circulating tumour DNA as a way to find the alteration.
Shares Tepotinib, MET exon 14 and MET-amplified non-small-cell lung cancer.
Shares VISION (tepotinib), MET exon 14 and MET-amplified non-small-cell lung cancer.
Shares Tepotinib, MET exon 14 and MET-amplified non-small-cell lung cancer, New England Journal of Medicine.
Shares Tepotinib, MET exon 14 and MET-amplified non-small-cell lung cancer.
Shares Tepotinib, MET exon 14 and MET-amplified non-small-cell lung cancer.
Shares Tepotinib, MET exon 14 and MET-amplified non-small-cell lung cancer.
Shares VISION (tepotinib), Tepotinib, MET exon 14 and MET-amplified non-small-cell lung cancer.